Durect
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Their unique approach involves harnessing epigenetic modulation, with a focus on their lead drug candidate, larsucosterol, which has shown promising results in clinical trials for alcohol-associated hepatitis and other liver diseases. The company collaborates with various partners, develops innovative drug delivery technologies, and is committed to improving patient outcomes through scientific excellence and transparency.
Industries
Nr. of Employees
medium (51-250)
Durect
10240 Bubb Road, Cupertino, CA 95014-4166
Patents
Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
US-12226423-B2
View DetailsSustained release drug delivery systems with reduced impurities and related methods
US-11771624-B2
View DetailsPharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
US-11529420-B2
View DetailsCompositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
US-11406646-B2
View DetailsSustained release drug delivery systems with reduced impurities and related methods
US-11400019-B2
View Details
Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
US-12226423-B2
View DetailsSustained release drug delivery systems with reduced impurities and related methods
US-11771624-B2
View DetailsPharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
US-11529420-B2
View DetailsCompositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
US-11406646-B2
View DetailsSustained release drug delivery systems with reduced impurities and related methods
US-11400019-B2
View DetailsProducts
Intravenous epigenetic modulator candidate for acute organ injury and liver disease
An endogenous small-molecule epigenetic modulator in clinical development that inhibits DNMT activity to reduce DNA hypermethylation and modulate pathways linked to cell death, inflammation and regeneration; being evaluated for severe alcohol-associated hepatitis and other acute organ injuries.
Non-opioid sustained-release bupivacaine injection for postsurgical analgesia
A sustained-release bupivacaine infiltration product approved for postsurgical analgesia with up to 72 hours of effect; commercialization rights licensed for certain territories with other regions retained by the developer.
Implantable osmotic infusion pumps and accessories for laboratory animals
Miniature implantable osmotic pumps and accessories designed for continuous delivery of drugs, hormones or test agents in mice, rats and other laboratory animals for durations from 1 day to 6 weeks; intended for research use only.
Intravenous epigenetic modulator candidate for acute organ injury and liver disease
An endogenous small-molecule epigenetic modulator in clinical development that inhibits DNMT activity to reduce DNA hypermethylation and modulate pathways linked to cell death, inflammation and regeneration; being evaluated for severe alcohol-associated hepatitis and other acute organ injuries.
Non-opioid sustained-release bupivacaine injection for postsurgical analgesia
A sustained-release bupivacaine infiltration product approved for postsurgical analgesia with up to 72 hours of effect; commercialization rights licensed for certain territories with other regions retained by the developer.
Implantable osmotic infusion pumps and accessories for laboratory animals
Miniature implantable osmotic pumps and accessories designed for continuous delivery of drugs, hormones or test agents in mice, rats and other laboratory animals for durations from 1 day to 6 weeks; intended for research use only.
Services
End-to-end formulation services including preformulation, optimization, small-scale production and scale-up for depot and long-acting injectable products.
Production of GLP batches and study oversight to support toxicology requirements for IND and clinical development.
Technology transfer, process development and GMP batch production to supply Phase 1–3 clinical trials.
Development and validation of assays to support PK/PD, biomarker and toxicokinetic analyses.
Feasibility studies, licensing agreements, development collaborations and commercialization planning including regional rights arrangements.
Commercial sales, distribution and technical support for miniature implantable osmotic infusion pumps and accessories for laboratory animal research.
End-to-end formulation services including preformulation, optimization, small-scale production and scale-up for depot and long-acting injectable products.
Production of GLP batches and study oversight to support toxicology requirements for IND and clinical development.
Technology transfer, process development and GMP batch production to supply Phase 1–3 clinical trials.
Development and validation of assays to support PK/PD, biomarker and toxicokinetic analyses.
Feasibility studies, licensing agreements, development collaborations and commercialization planning including regional rights arrangements.
Commercial sales, distribution and technical support for miniature implantable osmotic infusion pumps and accessories for laboratory animal research.
Expertise Areas
- Epigenetic therapeutics development
- Clinical trial management and multi-center execution
- Long-acting injectable and depot formulation development
- Preclinical pharmacology and animal model studies
Key Technologies
- Epigenetic modulation targeting DNA methylation (DNMT inhibition)
- High-viscosity sucrose acetate isobutyrate (SAIB)-based depot carriers
- Biocompatible bioerodible depot formulations for controlled release
- Noncovalent complexation to stabilize biologics and control solubility